ACB vs CRON: Which Is the Better Buy in 2026?

Last updated October 2026

Short answer

CRON is the larger of the two ($1.18B market cap): the incumbent the market prices for continued execution (-80.25x forward earnings, beta 1.20). ACB is the smaller challenger ($252.61M), priced similarly on forward earnings (-36.27x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ACB vs CRON: the tie-breaker metrics

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Metric	ACB	CRON	What it tells you
Market cap	$252.61M	$1.18B	Size. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E	-36.27	-80.25	Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta	1.42	1.20	Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range	38% of range	70% of range	Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book	0.68	1.11	How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how ACB and CRON affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACB and CRON share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACB and CRON exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Aurora Cannabis (ACB) do?

Aurora Cannabis is a Canadian licensed cannabis producer that has spent the past several years reinventing itself. Once one of the most hyped names of the 2018-2019 cannabis boom, it has since exited low-margin Canadian consumer (recreational) cannabis and non-core operations to concentrate on global medical cannabis, which carries higher and more durable margins. In its fiscal 2026 (ended March 31, 2026) the company reported record medical results: global medical net revenue grew sharply, international medical revenue rose even faster (led by Germany and Poland), and adjusted EBITDA and free cash flow were positive, a real shift from years of cash burn. On a GAAP basis, however, Yahoo Finance data show fiscal 2026 revenue of about 321 million and a net loss of about 122 million (Canadian dollars), with large losses in two quarters. International medical, its highest-margin segment, now makes up a majority of medical revenue. To feed that demand, Aurora acquired Safari Flower Company, an EU-GMP certified European cultivator, completed the divestiture of its controlling stake in Bevo Agtech in February 2026, and in October 2026 finished an expansion of its European EU-GMP facility that it says more than doubles expected annual flower output.

Full ACB guide

What does Cronos Group (CRON) do?

Cronos Group Inc. is a Canada-based, globally focused cannabis company that concentrates on building consumer brands and monetizing intellectual property rather than owning the full, capital-intensive cultivation chain. Its portfolio spans Spinach (a top-selling recreational brand in Canada across edibles, vapes, and flower), PEACE NATURALS (a global medical brand distributed in Canada, Israel, Germany, and the UK), the luxury CBD line Lord Jones, and LIT. Much of the long-running investment story traces to 2019, when tobacco giant Altria invested roughly CA$2.4 billion for a large equity stake, which today sits near 41% ownership. That deal left Cronos with an unusually strong balance sheet: about $797 million of cash against roughly $1.3 million of debt at June 30, 2026, a figure equal to about two-thirds of the company's roughly $1.2 billion market value.

Full CRON guide

ACB vs CRON: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

ACB drivers: International medical cannabis growth; The Curaleaf bid and strategic review.
CRON drivers: Fortress balance sheet and Altria backing; Brand-led, asset-light model.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. For CRON, the biggest risk is regulatory: cannabis remains federally illegal in the US, and reform timelines (rescheduling, SAFE banking, legalization) have slipped repeatedly, so much of the bull case depends on events Cronos cannot control.

ACB or CRON: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ACB if you believe its drivers more; CRON if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACB and CRON guides.

ACB vs CRON: the full fundamentals

ACB. Aurora trades below book value and under one times sales, a discount that tracks its losses and dilution history, but in October 2026 the price is also being set by the Curaleaf bid: the shares sit about 20% below the roughly $5 headline offer, since most of that value is in Curaleaf stock and the board opposes it. Be cautious with per-share comparisons across time given the reverse-split history, and check the current share count, cash position, and the status of the offer directly in filings. Fiscal second-quarter results are expected in early November 2026.

CRON. At about $1.2 billion, Cronos trades at roughly 17 times trailing earnings, but cash covers about two-thirds of that value, so the market is assigning only around $400 million to the operating business and the policy option. Trailing profit leans on non-operating income, which is why the forward P/E turns negative. The November 5, 2026 Q3 report, with consensus near $73.4 million of revenue and EPS of $0.05, plus the first CanAdelaar contribution, will show how much of the 2026 growth is durable.

Headline figures (approximate, October 2026): ACB shows market cap ~$252M at ~$3.98 a share (Oct 16, 2026), revenue (ttm) ~314M (Canadian dollars), down ~9% YoY in the latest quarter, net income (ttm) ~-52M; Q1 FY2027 net loss only ~-4M, eps (latest quarter) ~-$0.07 vs ~-$0.21 estimate; CRON shows share price (oct 16, 2026) ~$3.27; up ~21% YTD and ~32% over 1 year, market cap ~$1.2 billion, revenue (q2 2026) ~$74.4 million, up ~58% year over year, margins (ttm) Gross ~43%, operating ~15%.

The bottom line: ACB vs CRON

ACB and CRON are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACB and CRON exposure against your real portfolio. It is not an investment adviser.

Wondering how ACB or CRON fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Investing in Aurora Cannabis with AI

Connect the broker you already use and ask Walnut's AI how ACB fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does ACB fit me?

FAQ

What is the difference between ACB and CRON?

Aurora Cannabis is a Canadian licensed cannabis producer that has spent the past several years reinventing itself. Cronos Group Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ACB or CRON the better stock?

Neither is universally better. CRON is the larger incumbent; ACB is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ACB or CRON?

On forward P/E (as of October 2026), ACB trades at -36.27x and CRON at -80.25x, so CRON is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ACB and CRON?

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ACB vs CRON?

ACB: The central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. The takeover contest adds a new kind of volatility: if Curaleaf's offer lapses or is withdrawn and no alternative deal emerges, the shares could give back much of the roughly 49% three-month gain, while holders who tender would mostly receive Curaleaf stock, carrying that company's own risks. Even after the medical turnaround, management guided fiscal 2027 EBITDA lower, partly due to reduced Canadian medical reimbursement rates from April 2026, and revenue fell about 9% year over year in the June 2026 quarter. As a small-cap in a small, fast-changing industry, Aurora is heavily exposed to regulation: a policy change in Germany, Poland, Canada, or any key market can swing results quickly, and the whole sector is prone to sharp sentiment-driven moves. Currency swings between the Canadian dollar, euro, and US dollar affect reported results. Competition from Tilray, Canopy Growth, Curaleaf and local European producers is intense. The shares are volatile and speculative, and the stock has no dividend. CRON: The biggest risk is regulatory: cannabis remains federally illegal in the US, and reform timelines (rescheduling, SAFE banking, legalization) have slipped repeatedly, so much of the bull case depends on events Cronos cannot control. Profit quality is a second issue: trailing net income of about $70 million is far above trailing EBITDA of about $11.9 million, so a large part of reported earnings comes from interest and other non-operating items, and analysts expect a small loss on a forward basis. Canada's recreational market is oversupplied and price-competitive, pressuring margins. International expansion adds execution, currency, and integration risk, now concretely with CanAdelaar, whose EBITDA has declined as Dutch competition increased and whose business depends on a pilot program rather than permanent law. The proposed $10 million class-action settlement still needs court approval on November 19, 2026. The Altria stake is a double edge: it provides support but also concentrates influence and ties Cronos's fate partly to Altria's strategy. Finally, because so much value is the cash pile, capital-allocation decisions matter enormously to whether that balance sheet compounds or erodes.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ACB or CRON; figures are approximate and dated (as of October 2026). Verify current data before investing.